Whether immunotherapy biomarkers in previous studies (TMB, MSI, PD-L1, etc.) have equivalent predictive value for G/GEJ remains to be verified. In this phase II clinical trial of tislelizumab in combination with chemotherapy, potential therapy-related biomarkers in tumor samples, and changes in...
These patients should receive immunotherapy regardless of their PD-L1 expression status, as tumors with MSI-H status are known to be responsive to treatment with PD-1 inhibitors [15]. In response to the FDA ODAC recommendations, we evaluated PD-L1 further as a predictive biomarker of the ...
38 pts with genomic profiling: Wnt activating mutations in 12 pts, no MSI-H. 4 pts were IO experienced. Median number of cycles 2 (1, 19). 12 pts remain on therapy. 19 pts (37%) experienced D-related adverse events (AE); 74% were G1/2. Most common regimen related AEs: fatigue...